Obesity

Obesity and its causes are the focus of extensive research evaluating new therapeutic targets. Get an at-a-glance update on progress and FDA approvals during 2021

In patients with biopsy-proven NASH, the SPLENDOR study is the first to report a medical modality associated with decreased risk of major adverse events.

Weight bias themes in primary care are the subject of contemporary research. Which options you choose to these 8 questions may offer insight into your own unconscious prejudices.

In our latest podcast episode, an obesity expert talks weight bias in health care, its widespread impact, and the advocacy work that is being done to change the narrative.

Weight bias or stigma in healthcare settings, whether explicit or implicit, may keep patients from getting care. Find a review of the recent literature in this slide show.

Semaglutide 2.4 mg led to clinically significant weight loss and improvements in cardiometabolic risk factors in adults with moderate or severe obesity, suggests new research from ObesityWeek 2021.

The evidence that obesity is pathophysiologic dysfunction in the human body places it squarely in the realm of chronic disease, according to obesity specialist Kaplan. Let’s treat it accordingly.

Primary care leadership is essential to the future of obesity medicine, says Kaplan, but treatment needs to be within the normal scope of primary care practice. Hear him explain.

Recognizing obesity as chronic pathophysiologic dysfunction and explaining that to a patient will make them remarkably more receptive to all other discussions about treatment, says obesity specialist Kaplan.

ObesityWeek 2021. Weight loss with semaglutide was more than 2 times greater than with liraglutide in the 68-week placebo-controlled trial of the 2 GLP-1 RAs.